Simon Parreau1,2, Jérémie Jacques3,4, Stéphanie Dumonteil5, Sylvain Palat5, Sophie Geyl3, Guillaume Gondran5, Holy Bezanahary5, Eric Liozon5, Julie Azaïs5, Stéphanie Colombie5, Marie-Odile Jauberteau6, Véronique Loustaud-Ratti3, Kim-Heang Ly5,6, Anne-Laure Fauchais5,6. 1. Internal Medicine Department, Limoges University Hospital, 16 rue du Professeur Bernard Descottes, 87042, Limoges, France. simon.parreau@hotmail.com. 2. EA 3842 - Cellular Homeostasis and Diseases, Faculty of Medicine, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France. simon.parreau@hotmail.com. 3. Gastroenterology Department, Limoges University Hospital, 2 Avenue Martin Luther King, 87042, Limoges, France. 4. BioEM, UMR 7252, CNRS, Limoges, France. 5. Internal Medicine Department, Limoges University Hospital, 16 rue du Professeur Bernard Descottes, 87042, Limoges, France. 6. EA 3842 - Cellular Homeostasis and Diseases, Faculty of Medicine, University of Limoges, 2 rue du Docteur Marcland, 87025, Limoges, France.
Abstract
BACKGROUND: Abdominal symptoms in patients with primary Sjögren syndrome (pSS) are poorly documented. The objective of the study was to describe the abdominal symptoms of patients with pSS and to assess their association with characteristics of the disease. METHODS: One hundred and fifty patients with pSS were evaluated using a composite global symptom score for abdominal symptoms and their severity. Data concerning the clinical and biological characteristics of pSS and abdominal disorders were also collected. RESULTS: Of the patients with pSS, 95% suffered from abdominal symptoms (median global symptom score 7.5 ± 5.5 points out of 30). More than half of the patients experienced abdominal tension (68%), upper abdominal pain (54%), abdominal discomfort (58%) and/or constipation (54%). Regarding the pSS activity, in relation to European League Against Rheumatism (EULAR) Sjögren syndrome disease activity index score items, general and central nervous system involvement wereassociated with a high global symptom score. The EULAR Sjogren Syndrome Patient Reported Index (ESSPRI) symptom score was positively correlated with the global symptom score (p < 0.01). Multivariate analysis showed a significant association between a high global symptom score and SSA seronegativity, gastroparesis, and ESSPRI score (p < 0.01 for each). CONCLUSIONS: The majority of patients with pSS suffered abdominal symptoms. There is currently no therapeutic recommendation because of the lack of information on the underlying pathophysiological mechanisms. TRIAL REGISTRATION: NCT03157011 . Date of registration: July 17, 2017.
BACKGROUND: Abdominal symptoms in patients with primary Sjögren syndrome (pSS) are poorly documented. The objective of the study was to describe the abdominal symptoms of patients with pSS and to assess their association with characteristics of the disease. METHODS: One hundred and fifty patients with pSS were evaluated using a composite global symptom score for abdominal symptoms and their severity. Data concerning the clinical and biological characteristics of pSS and abdominal disorders were also collected. RESULTS: Of the patients with pSS, 95% suffered from abdominal symptoms (median global symptom score 7.5 ± 5.5 points out of 30). More than half of the patients experienced abdominal tension (68%), upper abdominal pain (54%), abdominal discomfort (58%) and/or constipation (54%). Regarding the pSS activity, in relation to European League Against Rheumatism (EULAR) Sjögren syndrome disease activity index score items, general and central nervous system involvement wereassociated with a high global symptom score. The EULAR Sjogren Syndrome Patient Reported Index (ESSPRI) symptom score was positively correlated with the global symptom score (p < 0.01). Multivariate analysis showed a significant association between a high global symptom score and SSA seronegativity, gastroparesis, and ESSPRI score (p < 0.01 for each). CONCLUSIONS: The majority of patients with pSS suffered abdominal symptoms. There is currently no therapeutic recommendation because of the lack of information on the underlying pathophysiological mechanisms. TRIAL REGISTRATION: NCT03157011 . Date of registration: July 17, 2017.
Authors: L Kovács; M Papós; R Takács; R Róka; Z Csenke; A Kovács; T Várkonyi; L Pajor; L Pávics; G Pokorny Journal: Clin Exp Rheumatol Date: 2003 Nov-Dec Impact factor: 4.473
Authors: Radjiv Goulabchand; Alain Makinson; Jacques Morel; Philine Witkowski-Durand-Viel; Nicolas Nagot; Paul Loubet; Camille Roubille; Danièle Noel; David Morquin; Kim Henry; Thibault Mura; Philippe Guilpain Journal: Ann Med Date: 2022-12 Impact factor: 5.348